CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsAltman Z-Score -0.06: distress zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
690.07MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.22xvs all stocks
52-Week Change
16.67%vs all stocks
Market Capitalization
690.07MUSDvs all stocks (USD)
Enterprise Value
535.81MUSDvs all stocks (USD)
Forward P/E
-3.51xvs Biotechnology peers
Price to Book (MRQ)
3.56xvs Biotechnology peers
Enterprise to EBITDA
-2.57xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-51.54%vs Biotechnology peers
Return on Equity (TTM)
-105.26%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 26, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-208.39MUSDvs all stocks (USD)
Net Income (TTM)
-202.67MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-193.03MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-115.99MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 26, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-216.41MUSDvs all stocks (USD)
Pre-tax Income
-206.69MUSDFY2025 · Dec 31, 2025Net Income
-206.69MUSDFY2025 · Dec 31, 2025EBIT
-216.41MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-213.76MUSDFY2025 · Dec 31, 2025Research & Development
184.70MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
29.06MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
9.72MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-206.69MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-190.17MUSDFY2025 · Dec 31, 2025Free Cash Flow
-190.31MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
163.08MUSDFY2025 · Dec 31, 2025Income Tax Paid
5.07MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-206.69MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
2.17MUSDFY2025 · Dec 31, 2025Stock-based Compensation
16.42MUSDFY2025 · Dec 31, 2025Other Non-cash Items
1.52MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
4.49MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-8.08MUSDFY2025 · Dec 31, 2025Capital Expenditures
-137.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-212.21MUSDFY2025 · Dec 31, 2025Sale of Investments
402.40MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
190.05MUSDFY2025 · Dec 31, 2025Other Financing Charges
-1.62MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
107.94MUSDFY2025 · Dec 31, 2025Shares Outstanding
174.60MSharesUpdated Sep 26, 2026Float Shares
163.79MSharesUpdated Sep 26, 2026Shares Short
32.09MSharesUpdated Sep 26, 2026Short Ratio
12.60daysvs all stocks
Short % of Shares Outstanding
17.92%vs all stocks
% Held by Insiders
0.42%vs all stocks
% Held by Institutions
103.01%vs all stocks
Total Cash (MRQ)
209.24MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.10USDUpdated Sep 26, 2026Total Debt (MRQ)
24.65MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1325xvs Biotechnology peers
Current Ratio (MRQ)
5.53xvs Biotechnology peers
Book Value per Share (MRQ)
1.07USDUpdated Sep 26, 2026Total Assets
277.57MUSDvs all stocks (USD)
Total Current Assets
242.19MUSDFY2025 · Dec 31, 2025Total Liabilities
65.92MUSDFY2025 · Dec 31, 2025Total Non-current Assets
35.38MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
23.29MUSDFY2025 · Dec 31, 2025Total Current Liabilities
42.63MUSDFY2025 · Dec 31, 2025Cash
2.01MUSDFY2025 · Dec 31, 2025Cash Equivalents
160.04MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
162.05MUSDFY2025 · Dec 31, 2025Other Short-term Investments
76.29MUSDFY2025 · Dec 31, 2025Accounts Payable
14.93MUSDFY2025 · Dec 31, 2025Short-term Debt
2.91MUSDFY2025 · Dec 31, 2025Other Current Liabilities
509.00KUSDFY2025 · Dec 31, 2025Long-term Debt
23.29MUSDFY2025 · Dec 31, 2025Common Stock (Book)
149.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-917.39MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
211.65MUSDvs all stocks (USD)
52-Week Low
2.54USDUpdated Sep 26, 202652-Week High
7.18USDUpdated Sep 26, 202652-Week Change
16.67%vs all stocks
Beta
1.22xvs all stocks
50-Day MA
4.99USDUpdated Sep 26, 2026200-Day MA
5.39USDUpdated Sep 26, 2026Avg 10-Day Volume
3.30MSharesUpdated Sep 26, 2026Avg 30-Day Volume
2.87MSharesUpdated Sep 26, 2026Diluted EPS (TTM)
-1.13USDUpdated Sep 26, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 5.53Altman Z-Score: -0.06
Financial Health
Altman Z-Score -0.06: distress zoneCritical
Altman Z-Score: -0.06
Low earnings qualitySignificant
Earnings Quality Score: -0.73
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Hunan Fangsheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Gen Ilac ve Saglik Urunleri A.S.
Tier 1ProductionApproval-Gated PipelineRule
Revenio Group Oyj
Tier 1ProductionApproval-Gated PipelineRule
ChemPartner Pharmatech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Zhejiang Anglikang Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Seers Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ironwood Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Wecome Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Collegium Pharmaceutical Inc.
Tier 1ProductionApproval-Gated PipelineRule
MiMedx Group, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Anhui Tatfook Technology Co., Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Finolex Industries Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Suzhou Electrical Apparatus Science Academy Co. Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity